Systemic Steroids
PreclinicalSmall molecule
Systemic Steroids is one of 29 small molecule programs targeting Vitiligo. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Trexall
Jazz PharmaceuticalsApproved
Cosentyx
NovartisApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Asmanex
PPerrigo Company
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Adrucil
EElorac, Inc.
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Rinvoq
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sudden Sensorineural Hearing Loss1 trial
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Unknown status·—·Phase 2·NCT05403229·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systemic Steroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Bordeaux